Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics

Amneal Pharmaceuticals, Inc. (AMRX): $1.27

-0.02 (-1.55%)

POWR Rating

Component Grades














  • Growth is the dimension where AMRX ranks best; there it ranks ahead of 99.4% of US stocks.
  • The strongest trend for AMRX is in Sentiment, which has been heading down over the past 177 days.
  • AMRX's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).

AMRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AMRX is 7.41 -- better than 94.66% of US stocks.
  • AMRX's price/sales ratio is 0.18; that's higher than the P/S ratio of just 5.43% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 12.31 for AMNEAL PHARMACEUTICALS INC; that's greater than it is for 94.27% of US stocks.
  • If you're looking for stocks that are quantitatively similar to AMNEAL PHARMACEUTICALS INC, a group of peers worth examining would be AGS, CEMI, NLST, SEAC, and MSGM.
  • Visit AMRX's SEC page to see the company's official filings. To visit the company's web site, go to

AMRX Valuation Summary

  • AMRX's price/sales ratio is 0.2; this is 95.74% lower than that of the median Healthcare stock.
  • AMRX's price/sales ratio has moved down 5.5 over the prior 61 months.

Below are key valuation metrics over time for AMRX.

Stock Date P/S P/B P/E EV/EBIT
AMRX 2023-03-24 0.2 1.4 -3.1 91.7
AMRX 2023-03-23 0.2 1.3 -3.1 91.5
AMRX 2023-03-22 0.2 1.4 -3.2 92.2
AMRX 2023-03-21 0.2 1.6 -3.6 93.4
AMRX 2023-03-20 0.2 1.5 -3.3 92.5
AMRX 2023-03-17 0.2 1.5 -3.3 92.5

AMRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRX has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
  • AMRX's asset turnover comes in at 0.514 -- ranking 77th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AMRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.514 0.343 0.037
2021-03-31 0.495 0.320 0.031
2020-12-31 0.483 0.315 0.032
2020-09-30 0.466 0.304 0.028
2020-06-30 0.440 0.283 0.063
2020-03-31 0.419 0.270 0.060

AMRX Stock Price Chart Interactive Chart >

Price chart for AMRX

AMRX Price/Volume Stats

Current price $1.27 52-week high $4.60
Prev. close $1.29 52-week low $1.24
Day low $1.24 Volume 1,141,700
Day high $1.30 Avg. volume 1,108,658
50-day MA $1.99 Dividend yield N/A
200-day MA $2.42 Market Cap 385.59M

Amneal Pharmaceuticals, Inc. (AMRX) Company Bio

Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.

AMRX Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRX Latest Social Stream

Loading social stream, please wait...

View Full AMRX Social Stream

Latest AMRX News From Around the Web

Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Hello, everyone. And welcome to the Amneal Fourth Quarter 2022 Earnings Conference Call. My name is Bruno, and I’ll be operating your call today. I will now turn the call over to Amneal’s Head of Investor Relations, Tony DiMeo. Please go ahead. […]

Yahoo | March 6, 2023

Q4 2022 Amneal Pharmaceuticals Inc Earnings Call

Q4 2022 Amneal Pharmaceuticals Inc Earnings Call

Yahoo | March 3, 2023

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 2, 2023

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

BRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.

Yahoo | March 2, 2023

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

BRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") announced its results today for the fourth quarter and full year ended December 31, 2022.

Yahoo | March 2, 2023

Read More 'AMRX' Stories Here

AMRX Price Returns

1-mo -41.20%
3-mo -36.18%
6-mo -37.13%
1-year -69.91%
3-year -57.67%
5-year -93.47%
YTD -36.18%
2022 -58.46%
2021 4.81%
2020 -5.19%
2019 -64.38%
2018 -18.74%

Continue Researching AMRX

Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:

Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7454 seconds.